Krizal Lifescience Profile
Key Indicators
- Authorised Capital ₹ 0.45 M
- Paid Up Capital ₹ 0.45 M
- Company Age 8 Year, 4 Days
- Last Filing with ROC 31 Mar 2018
- Revenue Growth %
- Profit Growth 404.57%
- Ebitda 488.57%
- Net Worth 17.92%
- Total Assets 274.31%
About Krizal Lifescience
Krizal Lifescience Private Limited (KLPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 February 2017 (Eight years 4 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.45 M and a paid-up capital of Rs 0.45 M, as per Ministry of Corporate Affairs (MCA) records.
Jayesh Mhatre, Anant Mhatre, Rajendra Patil, and Two other members serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999MH2017PTC291481
- Company No.
291481
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Feb 2017
- Date of AGM
27 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Krizal Lifescience?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayesh Mhatre  | Director | 21-Feb-2017 | Current |
| Anant Mhatre | Director | 21-Feb-2017 | Current |
| Rajendra Patil | Director | 14-Sep-2024 | Current |
| Rajashri Patil | Director | 14-Sep-2024 | Current |
| Kamini Sharma | Director | 14-Sep-2024 | Current |
Financial Performance of Krizal Lifescience.
Krizal Lifescience Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 404.57% increase in profit. The company's net worth Soared by an impressive increase of 17.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Krizal Lifescience?
In 2018, Krizal Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Krizal Lifescience?
Unlock and access historical data on people associated with Krizal Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krizal Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krizal Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.